ClinicalTrials.gg

Program

tulmimetostat

Also written as “Tulmimetostat”, “Tulmimetostat DL1 QD” and “Tulmimetostat DL2 QD”.

In Novartis's pipeline, EZH1, EZH2 inhibitor. Its studies are mostly in Bulbo-Spinal Atrophy, X-Linked · Prostatic Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by Novartis.

Furthest: phase 2, since Sep 23, 20193 company-led studies, 3 open or runningNext primary completion: Nov 9, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis33 open or runningphase 2since Sep 23, 2019Sep 23, 2019Nov 9, 2029phase 2 · NCT07206056
  • Named in Novartis’s own pipeline as DZR123 (tulmimetostat), phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 23, 2019First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT04104776 · 300 planned · United States, France, Italy and more
  2. Sep 16, 20252 phase 2 studiesNCT07190300, NCT07206056

Ahead

  1. Nov 9, 2029Primary completion: phase 2 study in Progressive Metastatic Castrate Resistant Prostate CancerNCT07206056
  2. Feb 27, 2030Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT04104776
  3. Aug 2, 2032Primary completion: phase 2 study in Bulbo-Spinal Atrophy, X-LinkedNCT07190300

TargetBeta

“EZH1, EZH2 inhibitor”the company's pipeline, read by Claude · source
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmaphase 22
valemetostatruleDaiichi Sankyophase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer · United States, Australia, Canada and more2RecruitingNov 9, 2029188
NCT07190300Bulbo-Spinal Atrophy, X-Linked · United States, Australia, Brazil and more2RecruitingAug 2, 2032181
NCT04104776Lymphoma, Large B-Cell, Diffuse · United States, France, Italy and more2RecruitingFeb 27, 2030300

How it is read

Names in the registry

  • “Tulmimetostat”, 2 entries
  • “Tulmimetostat DL1 QD”, 1 entry
  • “Tulmimetostat DL2 QD”, 1 entry
  • “Tulmimetostat DL3 QD”, 1 entry
  • “Tulmimetostat Doses 1 or 2 QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.